MBX Biosciences Q2 net loss $37.1M; cash $418.6M; canvuparatide Phase 3 recruiting; MBX 4291 7% weight loss

MBX Biosciences, Inc.

Net loss of $37.1M for Q2 2026 vs $19.4M in Q2 2025; R&D expenses rose to $31.0M from $17.7M.
Cash, cash equivalents and marketable securities of $418.6M as of June 30, 2026; expected to fund operations into 2029.
Phase 3 oPTimize trial of once-weekly canvuparatide in hypoparathyroidism now recruiting; sites activated.
MBX 4291 Phase 1 data: 7% mean weight loss at 8 weeks in first MAD cohort; 12-week MAD data on track for Q4 2026.
Steve Hoerter appointed Chairman and CEO; John Smither appointed CFO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.